Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease

Independent data monitoring committee advises lanabecestat is unlikely to meet primary endpoints, leading to decision to discontinue these trials INDIANAPOLIS, June 12, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY)... Biopharmaceuticals, Neurology Eli Lilly, AstraZeneca, lanabecestat, Alzheimer's disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news